Work

P-1185. Healthcare Resource Utilization (HCRU) of Critical Care Patients by Rank of Initiation from the Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam: Real-world Analysis (SPECTRA)

Year: 2026

Type: article

Abstract: Background A sub-analysis of SPECTRA (Study of Prescribing patterns and Effectiveness of Ceftolozane/Tazobactam Real-world Analysis) aimed to analyze healthcare resource utilization among 298 critical care patients stratified by the rank of chemotherapy or targeted therapy (C/T) initiation, focusing on 30-day all-cause readmissions, infection-related readmissions, prolonged hospital stays, and median length of hospital stays post-C/T initiation (n=298). Methods SPECTRA was a multicenter, observational study in patients (≥18 years of age) treated with ≥48 h of C/T in a hospital setting. For HCRU, data were categorized by the rank of C/T initiation: First Rank (N=74), Second Rank (N=70), Third Rank (N=57), Fourth Rank (N=43), Fifth Rank (N=26), and Sixth or more Rank (N=28). The study examined 30-day all-cause readmission rates, 30-day infection-related readmission rates, the number of patients remaining hospitalized 30 days post-C/T initiation, and median hospital length of stay overall and post-C/T initiation for patients discharged within 30 days. Results 30-day All-Cause Readmission Rate was 3.4% (variations:1.4% to 4.7% across ranks). 30-day infection-related readmission rate averaged 1.7% overall, (variations: 0% to 3.8%). Patients remaining hospitalized 30 Days after C/T initiation (n=64; 21.5%) were predominantly in the first four ranks. Median hospital length of stay (LOS) was 59.0 days (52.0-72.0). Median Post-C/T LOS for patients discharged within 30 Days was 8.0 days overall, with durations ranging from 4.0 to 12.0 days. Conclusion In conclusion, the examination of HCRU among critical care patients in the SPECTRA study reveals variations in readmission rates and hospital lengths of stay by the rank of C/T initiation. Further research is warranted to explore factors influencing these variations in HCRU, by novel antibiotics such as C/T. Future research may benefit antimicrobial stewardship and resource management in critical care environments. Disclosures Emre Yucel, PhD, Merck & Co., Ltd: Stocks/Bonds (Public Company) Jessica Levy, n/a, Merck & Co., Ltd: Stocks/Bonds (Public Company)

Source: Open Forum Infectious Diseases

DOI: 10.1093/ofid/ofaf695.1378